Facilities

Samsung Biologics to start construction of Plant 5

20-Mar-2023 By Rachel Arthur

Samsung Biologics will begin construction of Plant 5 within the first half of this year: marking the first facility for its second Bio Campus.

UK boosts cell and gene therapy manufacturing with new facility

14-Mar-2023 By Rachel Arthur

The new Clinical Biotechnology Centre (CBC) in Bristol will expand the UK’s ability to make clinical grade products for the research and development of new cell and gene therapies.

Evonik opens new facility for pharmaceutical lipids in Germany

09-Mar-2023 By Rachel Arthur

Evonik has opened a new GMP facility to manufacture lipids for advanced pharmaceutical drug delivery applications, which is situated at the company’s site in Hanau, Germany.

Recipharm’s Arranta Bio expands RNA process development capacity by 50%

09-Mar-2023 By Jane Byrne

Arranta Bio, a Recipharm company, has doubled capacity at its Massachusetts facility for process development services supporting RNA therapeutics.

Sandoz to build new biologics production plant in Slovenia, facility will support global demand for biosimilars

09-Mar-2023 By Jane Byrne

Sandoz is set to build a new biologics production plant in Lendava, Slovenia.

Moderna chooses Oxford for UK research and manufacturing mRNA hub

06-Mar-2023 By Rachel Arthur

Moderna’s UK Innovation and Technology Centre (MITC) will be located at the Harwell Campus in Oxford, and is expected to open in 2025.

Daiichi Sankyo to establish Japan’s first mRNA production facility

22-Feb-2023 By Jane Byrne

Daiichi Sankyo is kitting out a plant, based near Tokyo in Kitamoto, with equipment to enable the production of an mRNA vaccine against COVID-19, according to a Nikkei Asia report.

Minaris to accelerate clinical readiness of LIfT BioSciences’ cell therapy candidate

16-Feb-2023 By Jane Byrne

Minaris Regenerative Medicine, a contract development and manufacturing organization (CDMO) for cell and gene therapies, is pairing up with LIfT BioSciences on development and manufacturing for a first-generation advanced therapy medicinal product (ATMP).

Lotte Biologics has big ambitions: new CDMO industry entrant unveils growth strategy

09-Feb-2023 By Jane Byrne

The South Korean player plans to expand its recently acquired US facility, to provide contract manufacturing services for Antibody Drug Conjugates (ADC), and to add drug product fill & finish facilities to establish a foothold in the North American...

Bionova Scientific aims to quadruple GMP biologics manufacturing capacity

06-Feb-2023 By Jane Byrne

The project is the first phase of a wider strategic initiative to expand capacity and enhance end-to-end biologics development and manufacturing services at the US CDMO.

New US CDMO launched to address viral vector supply bottleneck

01-Feb-2023 By Jane Byrne

Vector BioMed, a CDMO specializing in the manufacture of lentiviral vectors, launched this week; its first financing round was led by Viking Global Investors and Casdin Capital.

Lonza: Robust industry fundamentals are supportive of growth

25-Jan-2023 By Jane Byrne

Despite an uncertain macroeconomic environment, Lonza says its ‘resilient’ business model and sustained market demand delivered a strong financial performance in 2022, in line with the Swizterland based CDMO’s outlook.

Regenxbio initiates gene therapy trial for DMD as part of its AAV therapeutics strategy for 2025

24-Jan-2023 By Jane Byrne

Regenxbio has begun recruiting for its Phase I/2 gene therapy trial in Duchenne muscular dystrophy (DMD).

Needle-free future: Tackling vaccine delivery challenges

19-Jan-2023 By Jane Byrne

Biotech company, Vaxxas, has secured a partnership agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its needle-free vaccine-patch delivery technology for mRNA vaccines.

CBM looks to boost viral vector manufacturing capabilities in cell line deal

19-Jan-2023 By Jane Byrne

The unprecedented rise in approvals for new cell and gene therapies, and the increasing industry need for cell lines to support the production of therapeutics, has spurred US CDMO, the Center for Breakthrough Medicines (CBM), to act

US and Switzerland sign good manufacturing practice agreement

19-Jan-2023 By Rachel Arthur

An agreement between the two countries means they can use each other’s good manufacturing practice inspections of pharmaceutical manufacturing facilities and avoid the need for duplicate inspections.

UK ATMP clinical research picture remains positive despite challenging global environment

17-Jan-2023 By Jane Byrne

In 2022, the UK continued to have a signficant footprint in ATMP clinical research, with total ongoing trials increasing from 168 in 2021 to 178 in 2022, according to a new report.

Resilience to expand global footprint, collaborating on first GMP biopharma facility in UAE

17-Jan-2023 By Jane Byrne

National Resilience has secured an equity investment from Mubadala, an Abu Dhabi sovereign investor. The amount was not disclosed.

Lumen Bio: ‘We face 2023 with tremendous optimism’

16-Jan-2023 By Jane Byrne

Lumen Bioscience has been highlighting recent progress made on its clinical and regulatory journey while also announcing several funding milestones supporting the development of its therapeutics to prevent serious diarrheal diseases.

Delpharm acquires injectable drug development center in the Netherlands from Dr Reddy's

05-Jan-2023 By Jane Byrne

France headquartered CDMO, Delpharm, has expanded its pharmaceutical development services with the acquisition of the Leiden Development Centre from Dr Reddy's in the Netherlands.

Boost for Axplora’s antibody drug conjugate technology platform

15-Dec-2022 By Jane Byrne

The French National Agency for the Safety of Health Products (ANSM) has granted a pharmaceutical establishment license to Axplora’s Le Mans site.

GSK, Sanofi, and Takeda align with research communities to advance Singapore's biologics manufacturing capabilities

06-Dec-2022 By Jane Byrne

Global pharma giants, GSK, Sanofi, and Takeda, are set to collaborate with Singapore-based researchers to boost innovation in local biologics and vaccines manufacturing.

Recombinant specialist Sino Biological starts building first US manufacturing facility

01-Dec-2022 By Nick Taylor

Sino Biological has begun construction of its first US-based manufacturing facility at a 53-acre life science district in Houston.

Fujifilm invests $188m in new North Carolina cell culture media facility

23-Nov-2022 By Jane Byrne

Fujifilm Corporation is to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, in the US.

BioNTech acquires GMP manufacturing site in Singapore

14-Nov-2022 By Rachel Arthur

BioNTech will create an mRNA facility in Singapore through the acquisition of a Novartis site: which will become its Regional Headquarters and production center for the Asia Pacific region.

ReiThera opens new viral vector production manufacturing facility

03-Nov-2022 By Rachel Arthur

ReiThera has received operational authorization from the Italian Medicines Agency (AIFA) to open a new production area at its facility near Rome for the large-scale production of viral vectors for vaccines and gene therapy.

Thermo Fisher adds clinical research lab as part of $97m expansion

24-Oct-2022 By Ben Hargreaves

The company opens a bioanalytical lab in the US, which offers an additional 59,000-square-feet of space to the overall facility, making it “one of the largest laboratories of its kind.”

VGXI opens new HQ and manufacturing facility in Texas

24-Oct-2022 By Rachel Arthur

CDMO VGXI has officially opened its new headquarters and manufacturing facility in Conroe, Texas.

Andelyn Biosciences opens GMP manufacturing facility

20-Oct-2022 By Rachel Arthur

US gene therapy CDMO, Andelyn Biosciences, has opened a new GMP clinical and commercial manufacturing facility to support cell and gene therapy (CGT) development and manufacturing.

BioNTech to build mRNA center in Australia

11-Oct-2022 By Rachel Arthur

BioNTech will establish an mRNA research and innovation center in Victoria, alongside clinical scale manufacturing capabilities. Meanwhile, it has also pledged to step up clinical development of oncology therapies in the country.

Orca Bio expands manufacturing capabilities to take cell therapies through to commercialization

13-Sep-2022 By Rachel Arthur

Orca Bio, a biotech developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, will expand its current manufacturing capabilities with the construction of a new 100,000-square-foot commercial...

Biotimize opens fundraising round to build first biological CDMO in Brazil

05-Sep-2022 By Rachel Arthur

Biotimize has announced the opening of a $30m Series A fundraising round: with the investment set to enable Biotimize to build the first biological CDMO in Brazil and to become the first end-to-end biological CDMO in South America.

Applied StemCell expands manufacturing facility to support cell and gene therapies

30-Aug-2022 By Rachel Arthur

Applied StemCell is expanding its cGMP facility to increase its cell banking and cell product manufacturing capacity.

WuXi STA breaks ground on new Delaware manufacturing facility

17-Aug-2022 By BioPharma-Reporter

CRDMO WuXi STA has begun construction of a new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware.

Sartorius to acquire Albumedix for $502m

09-Aug-2022 By Rachel Arthur

Life science group Sartorius will acquire UK recombinant albumin-based solution company Albumedix.

RoslinCT and Lykan Bioscience combine to create advanced cell therapy CDMO

04-Aug-2022 By Rachel Arthur

Edinburgh CDMO RoslinCT and Massachusetts CDMO Lykan Bioscience will combine to create a global advanced therapies CDMO: offering significantly expanded manufacturing capacity.

Thermo Fisher Scientific expands New York cell culture media manufacturing site

04-Aug-2022 By Rachel Arthur

A $76m investment in the facility in Grand Island, New York, will increase capacity to produce raw materials used in manufacture of vaccines and biologic therapies.

Increased demand for aseptic filling sees Cytiva boost manufacturing capacity in Vancouver

28-Jul-2022 By Jane Byrne

This week saw Cytiva open a new 126 200 ft2 (11,724 m2) site in the greater Vancouver area, Canada.

Samsung Biologics on track to open ‘super plant’ in October

28-Jul-2022 By Rachel Arthur

Construction of Samsung Biologics’ Plant 4 is on schedule with operations set to start in October, the company confirmed in its Q2 results this morning.

Bavarian Nordic gets US and EU approval for Denmark fill finish vaccine facility

28-Jul-2022 By Rachel Arthur

Bavarian Nordic A/S has received approvals from the US and EU regulatory authorities to manufacture its Jynneos/Imvanex smallpox and monkeypox vaccine at its fill and finish facility in Denmark.

Astellas to create $70m biotech campus in San Francisco

25-Jul-2022 By Rachel Arthur

Astellas Pharma Inc. will build a biotechnology campus in South San Francisco: providing capabilities to develop cell and gene therapies.

WuXi Biologics to build CRDMO center in Singapore

21-Jul-2022 By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

Cytiva investing in additional resins manufacturing operations

18-Jul-2022 By Jane Byrne

Cytiva is investing in additional resins manufacturing operations, with the acquisition of a new facility in Muskegon, Michigan.

Samsung Bio reports progress in reducing Scope 1 and 2 emissions

13-Jul-2022 By Jane Byrne

Samsung Biologics says it is actively working to engage its suppliers to transition to net zero emissions in multiple areas and invest in renewable energy.

Fujifilm to invest $1.6bn and make its Hillerød facility in Denmark the largest end-to-end CDMO in Europe

30-Jun-2022 By Jane Byrne

Fujifilm Corporation is to invest US$1.6bn (€1.4bn) to boost the business of its subsidiary, Fujifilm Diosynth Biotechnologies (FDB), a contract development and manufacturing organization (CDMO).

Croda awarded $75m from US government to expand production of raw materials for mRNA vaccines

30-Jun-2022 By Jane Byrne

UK pharma group, Croda International, has inked a deal with the US government in which it will receive up to US$75m to expand its US manufacturing capacity for lipid systems.

Kite secures third approved cell therapy indication in Europe

28-Jun-2022 By Jane Byrne

The European Commission (EC) has approved Kite’s CAR T-cell therapy, Yescarta, (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.

Spanish CDMO adapts production capabilities, boosts workforce to meet rising viral vector demand

27-Jun-2022 By Jane Byrne

VIVEbiotech has completed the latest expansion phase of its lentiviral vector manufacturing capabilities; the development is aimed at alleviating the viral vector bottleneck for advanced therapies.

US: Merck doubles production capacity of ADC components

23-Jun-2022 By Jane Byrne

Merck has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, Wisconsin, US.

BIO International: US CDMO looks to plug critical cell therapy manufacturing capacity shortage

16-Jun-2022 By Jane Byrne

The BIO International Convention in San Diego this week heard the US-based Center for Breakthrough Medicines (CBM) is to speed up plans to build what it calls the largest cell therapy manufacturing operation worldwide.